Abstract

Protein tyrosine phosphatases (PTPs) are crucial regulators for numerous biological processes in nature. The dysfunction and overexpression of many PTP members have been demonstrated to cause fatal human diseases such as cancers, diabetes, obesity, neurodegenerative diseases and autoimmune disorders. In the past decade, considerable efforts have been devoted to the production of PTPs inhibitors by both academia and the pharmaceutical industry. However, there are only limited drug candidates in clinical trials and no commercial drugs have been approved, implying that further efficient discovery of novel chemical entities competent for inhibition of the specific PTP target in vivo remains yet a challenge. In light of the click-chemistry paradigm which advocates the utilization of concise and selective carbon-heteroatom ligation reactions for the modular construction of useful compound libraries, the Cu(I)-catalyzed azide-alkyne 1,3-dipolar cycloaddition reaction (CuAAC) has fueled enormous energy into the modern drug discovery. Recently, this ingenious chemical ligation tool has also revealed efficacious and expeditious in establishing large combinatorial libraries for the acquisition of novel PTPs inhibitors with promising pharmacological profiles. We thus offer here a comprehensive review highlighting the development of PTPs inhibitors accelerated by the CuAAC click chemistry.

Highlights

  • Tyrosine phosphorylation (TP) is a fundamental mechanism modulating a number of important physiological processes of eukaryotes such as the communication between and within cells, the change in shape and motility of cells, cell proliferation and differentiation, gene transcription, mRNA processing, and the intraand intercellular transportations of molecules

  • Reversible tyrosine phosphorylation is governed by the balanced action of protein tyrosine kinases (PTKs) and proteintyrosine phosphatases (PTPs)

  • A novel series of sugar-salicylic acid hybrids were subsequently synthesized by CuAAC, in which compounds (IC50 = 8.7 μM) and (IC50 = 6.7 μM) having a benzylated glucosyl moiety were identified as low micromolar protein tyrosine phosphatase 1B (PTP1B) inhibitors with certain selectivity over other PTPs tested (3-fold over T cell PTP (TCPTP) and 8 to 15-fold over SHP-1, Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP-2) and LAR [leukocyte antigen-related protein]) (Fig. 3) [53]

Read more

Summary

INTRODUCTION

Tyrosine phosphorylation (TP) is a fundamental mechanism modulating a number of important physiological processes of eukaryotes such as the communication between and within cells, the change in shape and motility of cells, cell proliferation and differentiation, gene transcription, mRNA processing, and the intraand intercellular transportations of molecules. The PTPs constitute a large family of enzymes that parallel tyrosine kinases in their structural diversity and complexity. The number of genes only illustrates the minimal level of complexity as additional diversities are introduced through the use of alternative promoters, alternative mRNA splicing and posttranslational modifications. Biochemical and genetic studies indicate that protein phosphatases can exert both positive and negative effects on signaling pathways, and play crucial physiological roles in a variety of mammalian tissues and cells [4, 5]

PTPS AS DRUG TARGETS
CLICK-DERIVED PTPS INHIBITORS
SUMMARY AND PERSPECTIVE
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call